Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

New Imager to Aid Medical Research

February 8, 2011 6:39 am | News | Comments

Purdue University's Bindley Bioscience Center has installed a high-end imaging instrument to advance research in the areas of cancer, neuroscience, and cardiovascular and musculoskeletal diseases.

TOPICS:

Natco Challenging Tamiflu Patent

February 8, 2011 6:35 am | News | Comments

Gilead Sciences Inc. said that Natco Pharma Ltd. is challenging a patent on the flu drug Tamiflu. Tamiflu was developed by Gilead, which receives royalties on the drug's sale from Roche Holding AG.

TOPICS:

New Database Brings Researchers And Funds Together

February 8, 2011 6:33 am | News | Comments

In 2010, the National Institutes of Health was able to fund fewer than 25 percent of the research grant applications submitted to its 27 institutes and centers. In 2011, the National Health Council is giving unfunded NIH applications the potential for a new lease on life.

TOPICS:
Advertisement

King Pharma Delisting Stock

February 8, 2011 6:27 am | News | Comments

King Pharmaceuticals Inc. said it plans to voluntarily delist its stock from the New York Stock Exchange as it completes its sale to Pfizer Inc. The company said its stock will be listed through Feb. 28.

TOPICS:

IU Launches Personalized Medicine Institute

February 8, 2011 6:25 am | News | Comments

Indiana University has announced a major commitment to research in one of health care's most promising fields with the creation of the Indiana Institute for Personalized Medicine.

TOPICS:

Pharmasset Reports Higher Than Expected Losses

February 8, 2011 6:21 am | News | Comments

Clinical-stage drugmaker Pharmasset Inc. reported a wider fiscal first-quarter loss Monday on higher research and development costs. The company lost $23.5 million, compared with a loss of $13.9 million the same quarter a year prior.

TOPICS:

GSK Adds Safety Restrictions to Avandia Label

February 8, 2011 6:18 am | by Matthew Perrone | News | Comments

GlaxoSmithKline PLC said it has updated the labeling of its diabetes pill Avandia to include safety restrictions ordered by federal health authorities because of the drug's links to heart attack.

TOPICS:

Danaher Acquiring Beckman Coulter for $6.8B

February 7, 2011 9:04 am | News | Comments

Beckman Coulter, Inc. announced that it has entered into a definitive merger agreement under which Danaher will acquire all of Beckman Coulter's outstanding common stock for $83.50 per share in cash.

TOPICS:
Advertisement

Bioterror Detection Assay

February 7, 2011 7:31 am | Product Releases | Comments

Abbott has introduced the PLEX-ID Biothreat Assay, which is designed to detect and distinguish 17 different biothreat pathogens. This assay enables rapid and accurate detection of potentially dangerous microorganisms.

TOPICS:

Full Stroke Diaphragms

February 7, 2011 7:27 am | Drug Discovery & Development | Product Releases | Comments

Wilden, a leader in air-operated double-diaphragm pump technology, will be introducing its new Full Stroke PTFE Diaphragms for use on all of its AODD pump lines at INTERPHEX 2011.

TOPICS:

Fluorescent Peptides Help Nerves Glow

February 7, 2011 7:19 am | News | Comments

Accidental damage to thin or buried nerves during surgery can have severe consequences, from chronic pain to permanent paralysis. Scientists at the University of California, San Diego School of Medicine may have found a remedy.

TOPICS:

Research Connects 29 New Regions to IBD

February 7, 2011 7:17 am | News | Comments

An international team of researchers has made new links between 29 regions of the genome and ulcerative colitis. The new findings increase the total number of genome regions known to be associated with inflammatory bowel disease to 99.

TOPICS:

Acacia Wraps Up APD515 Trial

February 7, 2011 7:14 am | News | Comments

Acacia Pharma announces it has completed a Phase 1 clinical study of its product candidate APD515, an optimised oromucosal formulation of a currently marketed drug for the new use of treatment of dry mouth in advanced cancer patients.

TOPICS:

Regorafenib Receives Orphan Drug Status

February 7, 2011 7:12 am | News | Comments

Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumors by the U.S. Food and Drug Administration.

TOPICS:

Pfizer Buying Ferrosan Consumer Health Division

February 7, 2011 7:02 am | News | Comments

Pfizer Inc. said it will expand its European business by acquiring Ferrosan's consumer health care business which includes vitamins and skincare products. The New York drugmaker did not disclose financial terms of the deal.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading